Litigation Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
✉ Email this page to a colleague
Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
| Docket | ⤷ Try a Trial | Date Filed | 2017-06-26 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | Defendant | Referred To | |
| Patents | 6,926,907; 7,320,999; 8,399,514; 8,759,393 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biogen International GmbH v. Amneal Pharmaceuticals LLC
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Biogen International GmbH v. Amneal Pharmaceuticals LLC (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-08-31 | 166 | Stipulation of Dismissal | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ʼ999 patent”) and 8,399,514…8,399,514 (“the ’514 patent”) (collectively, the “Asserted Patents”): Biogen MA Inc. v. Impax Laboratories, …Stipulation grants no rights to Impax under any patents or other proprietary rights. … 26 June 2017 1:17-cv-00823-MN 835 Patent - Abbreviated New Drug Application(ANDA) Defendant | External link to document |
| 2019-03-07 | 236 | Memorandum Opinion | infringement of U.S. Patent Nos. 6,509,376 ("the ' 376 patent"), 7,320,999 ("the ' …393 patent"), and 8,399,514 ("the ' 514 patent") (collectively, "patents-in-suit…; 999 patent"), 7,619,001 ("the ' 001 patent"), 7,803 ,840 ("the ' 840 patent…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id. at 1321 (internal quotation marks omitted). The patent "specification | External link to document |
| 2019-10-11 | 315 | Stipulation of Dismissal | infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the ’999 patent”), and 8,399,514… alleging infringement of U.S. Patent No. 7,619,001 (“the ’001 patent”) by submission of Hetero’s ANDA…8,399,514 (“the ’514 patent”) by submission of Hetero’s Abbreviated New Drug Application (“ANDA”) No. 210500… Product”) prior to the expiration of the ’001 patent, i.e., June 20, 2020. 2. All claims… defenses, and counterclaims regarding the ’001 patent brought in C.A. No. 19-211 are dismissed without | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
